In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb)Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Comedication with ciprofloxacin does not change pharmacokinetics of mycophenolic acid after lung transplantation Source: Eur Respir J 2002; 20: Suppl. 38, 349s Year: 2002
The effects of erdosteine and caffeic acid phenethyl ester on the activities of some metabolic enzymes after cisplatin-induced nephrotoxicity in rats Source: Eur Respir J 2002; 20: Suppl. 38, 71s Year: 2002
A 5-aza-2?-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma Source: Eur Respir J 2011; 38: 1105-1116 Year: 2011
Anti-inflammatory and cytoprotective actions of the endogenous docosahexaenoic acid (DHA) electrophilic derivative 17-oxo-DHA Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
In vitro and in vivo activity of thiourea (ISO), a mycolic acid inhibitor, against multi drug resistant (MDR) strains of Mycobacterium tuberculosis (M. tb )Source: Eur Respir J 2005; 26: Suppl. 49, 700s Year: 2005
Inhibitory effect of caffeic acid phenethyl ester on bleomycine-induced lung fibrosis in rats Source: Eur Respir J 2002; 20: Suppl. 38, 487s Year: 2002
In vitro evaluation of Isoxyl, a mycolic acid inhibitor in combination with rifampicin and Isoniazide against mycobacteria other than M. tuberculosis Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy Source: Eur Respir J, 50 (3) 1700782; 10.1183/13993003.00782-2017 Year: 2017
Monitoring of amikacin-induced ototoxicity during the treatment of multidrug resistant tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Differential actions of the endogenous docosahexaenoic acid (DHA) electrophilic derivative 17-oxo-DHA in macrophages and bronchial epithelial cells Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013
Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Source: Eur Respir J 2009; 34: 145-155 Year: 2009
Overexpression of fatty acid synthase attenuate bleomycin induced lung injury/fibrosis via restoring mitochondrial dysfunction Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair Year: 2020
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study Source: Eur Respir J 2011; 37: 129-135 Year: 2011
The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-membered ring macrolide antibiotic) Source: Eur Respir J 2004; 24: Suppl. 48, 615s Year: 2004
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment Source: Eur Respir J 2015; 45: 554-557 Year: 2015